为乳腺癌中MEK5/ERK5通路进行基于网络的药物优先级和组合分析
Regan Odongo1, Asuman Demiroglu-Zergeroglu2, Tunahan Çakır3
1Department of Bioengineering, Faculty of Engineering, Gebze Technical University, Gebze, Kocaeli, 41400, Turkey. odongoregan@gmail.com.
BioData mining
|February 20, 2024
概括
这项研究优先考虑植物性化合物和药物组合用于乳腺癌治疗,使用针对MEK5/ERK5通路的网络药理方法. 热尼斯坦和几种FDA批准的药物显示出协同效应的组合疗法的前景.
科学领域:
- 系统药理学 系统药理学
- 网络药理学 网络药理学
- 癌症生物学 癌症生物学
背景情况:
- 全基因组表达数据为临床前药物评估提供了一种整体方法.
- MEK5/ERK5信号通路是最近在癌症中确定的一种药物标.
- 乳腺癌治疗可以从新的药物优先级策略中受益.
研究的目的:
- 应用基于网络的方法来优先考虑植物多,并确定乳腺癌的药物组合.
- 研究植物多和药物对MEK5/ERK5信号通路的系统性影响.
- 为了确定乳腺癌治疗的潜在协同药物组合.
主要方法:
- 构建和分析乱的蛋白质-蛋白质相互作用网络.
- 一个特定途径的网络药理学管道的应用.
- 转录组数据分析以确定候选药物和组合.
主要成果:
- 植物多和药物对光线A乳腺癌中MEK5/ERK5通路的系统性影响.
- 在乳腺癌治疗中,在植物多中优先考虑基因斯坦.
- 预测基因斯坦与几种FDA批准的药物以及已识别的新型"目标网络增强剂"药物的协同作用组合.
结论:
- 开发了一个用于药物优先级和组合治疗的计算框架,该框架针对乳腺癌中MEK5/ERK5通路.
- 提出的方法灵活,适用于其他复杂疾病.
- 这项研究为推进乳腺癌药物发现提供了强大的计算工具.
更多相关视频
相关概念视频
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
MAPK Signaling Cascades
5.5K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K


